LAP (TGF-β1) Antibody, anti-human, REAfinity™
Synonyms: TGFB1, CED, DPD1
RECOMBINANT
Bioz Star89/100 Bioz rating
2 Citations
Clone:
REA1214 | CH6-17E5.1
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for LAP (TGF-β1) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
PE
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-123-410, 130-123-415
Description:
Human peripheral blood cells (PBMCs) were either left unstimulated (left image) or stimulated with the Treg Expansion CD3/CD28 MACSiBead Particles and CD40 antibodies for 48 hours. Cells were then stained with Anti-LAP (TGF-β1) antibodies, as well as with CD4 and Anti-FoxP3 antibodies. For analysis, cells were pregated on CD4+ cells. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
Specifications for LAP (TGF-β1) Antibody, anti-human, REAfinity™
Overview

Clone REA1214 recognizes the N-terminal latency-associated peptide (LAP) of the transforming growth factor β1 (TGF-β1) dimer. TGF-β1 belongs to a family of homologous, disulfide-linked, homodimeric proteins. These highly pleiotropic cytokines inhibit proliferation of most cells, but can promote the growth of mesenchymal cells and enhance extracellular matrix formation. The pivotal function of TGF-β1 in the immune system is to mediate immunosuppression and maintain tolerance by regulating lymphocyte proliferation, differentiation, and survival. TGF-β1 is produced by many cell types, but is reported to be most abundant in mammalian platelets and bone. It is secreted predominantly as an inactive latent complex. After proteolytical processing of the TGF-β1 precursor, the resulting N-terminal latency-associated peptide (LAP) remains non-covalently associated with the TGF-β1 dimer. Mature and biologically active TGF-β1 can be released from the complex by action of proteases and/or conformational changes. LAP-TGF-β1 was described to be expressed on the cell surface of activated human regulatory T cells.

Additional information: Clone REA1214 displays negligible binding to Fc receptors.

Alternative names

TGFB1, CED, DPD1

Detailed product information

Technical specifications

Clone
REA1214
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
LAP (TGF-β1)
Molecular mass of antigen [kDa]
28
Distribution of antigen
platelets, bone
Entrez Gene ID
RRID
AB_2876922, AB_2876923, AB_2876986, AB_2876987

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for LAP (TGF-β1) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

You have previously chosen International as your location.
What do you want to do?